Compare ARCO & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARCO | AAPG |
|---|---|---|
| Founded | 2007 | 2009 |
| Country | Uruguay | China |
| Employees | N/A | 767 |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.0B |
| IPO Year | 2011 | N/A |
| Metric | ARCO | AAPG |
|---|---|---|
| Price | $8.66 | $21.16 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $8.60 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 1.1M | 1.9K |
| Earning Date | 05-20-2026 | 05-20-2026 |
| Dividend Yield | ★ 3.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.56 | $290.34 |
| Revenue Next Year | $3.48 | N/A |
| P/E Ratio | $7.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.51 | $20.11 |
| 52 Week High | $9.75 | $48.45 |
| Indicator | ARCO | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 47.29 | 35.99 |
| Support Level | $8.51 | $20.11 |
| Resistance Level | $8.98 | $25.23 |
| Average True Range (ATR) | 0.30 | 0.53 |
| MACD | -0.06 | -0.24 |
| Stochastic Oscillator | 14.63 | 5.04 |
Arcos Dorados Holdings Inc operates McDonald's branded restaurants in various countries and territories in Latin America and the Caribbean. The Company manages its business as distinct geographic segments and its operations are divided into three geographic divisions, as follows: Brazil, the North Latin American division, or NOLAD, which is comprised of Costa Rica, Mexico, Panama, Puerto Rico, Martinique, Guadeloupe, French Guiana and the U.S. Virgin Islands of St. Croix and St. Thomas and the South Latin American division, or SLAD, which is comprised of Argentina, Chile, Ecuador, Peru, Uruguay, Colombia, Venezuela, Trinidad and Tobago, Aruba and Curacao. Their menu includes hamburgers, McNuggets, salad, sandwiches, French fries, and others.
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.